Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENVB OTCMKTS:GPLB NASDAQ:GRI NASDAQ:ZVSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENVBEnveric Biosciences$1.32+3.1%$1.27$1.01▼$11.55$3.26M0.54785,209 shs149,488 shsGPLBGreen Planet Bioengineering$0.04$0.09$0.02▼$0.70$800K3.073,055 shsN/AGRIGRI Bio$1.82-6.7%$1.44$1.10▼$43.69$4.54M-1.62158,905 shs242,429 shsZVSAZyVersa Therapeutics$0.14-22.5%$0.60$0.14▼$4.20$696K0.822.48 million shs635,472 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENVBEnveric Biosciences0.00%+0.76%+4.76%+12.82%-82.91%GPLBGreen Planet Bioengineering0.00%0.00%-80.20%-63.64%+33.33%GRIGRI Bio0.00%+9.64%+30.00%+20.53%-93.81%ZVSAZyVersa Therapeutics0.00%-75.76%-79.28%-79.55%-96.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENVBEnveric Biosciences1.9328 of 5 stars3.52.00.00.01.10.01.3GPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/AN/AN/AGRIGRI Bio2.3998 of 5 stars3.54.00.00.00.60.01.3ZVSAZyVersa Therapeutics0.1109 of 5 stars0.01.00.00.01.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENVBEnveric Biosciences 3.00Buy$10.00657.58% UpsideGPLBGreen Planet Bioengineering 0.00N/AN/AN/AGRIGRI Bio 3.00Buy$22.001,108.79% UpsideZVSAZyVersa Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GPLB, GRI, ZVSA, and ENVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/A$7.68 per shareN/AZVSAZyVersa TherapeuticsN/AN/AN/AN/A$3.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-250.28%-195.57%8/11/2025 (Estimated)GPLBGreen Planet BioengineeringN/AN/A0.00∞N/AN/AN/AN/AN/AGRIGRI Bio-$8.21M-$11.56N/AN/AN/AN/A-275.15%-168.22%8/12/2025 (Estimated)ZVSAZyVersa Therapeutics-$9.41MN/A0.00N/AN/AN/A-109.54%-43.95%8/8/2025 (Estimated)Latest GPLB, GRI, ZVSA, and ENVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025GRIGRI Bio-$1.31N/AN/AN/AN/AN/A5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/A5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/A5/12/2025Q1 2025ZVSAZyVersa Therapeutics-$0.40-$0.73-$0.33-$0.73N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENVBEnveric BiosciencesN/AN/AN/AN/AN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/AN/AZVSAZyVersa TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENVBEnveric BiosciencesN/A4.084.08GPLBGreen Planet BioengineeringN/AN/AN/AGRIGRI BioN/A1.411.41ZVSAZyVersa TherapeuticsN/A0.180.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENVBEnveric Biosciences13.82%GPLBGreen Planet BioengineeringN/AGRIGRI Bio33.95%ZVSAZyVersa Therapeutics3.91%Insider OwnershipCompanyInsider OwnershipENVBEnveric Biosciences1.10%GPLBGreen Planet BioengineeringN/AGRIGRI Bio0.13%ZVSAZyVersa Therapeutics0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENVBEnveric Biosciences202.47 million2.45 millionNot OptionableGPLBGreen Planet Bioengineering120.01 millionN/ANot OptionableGRIGRI Bio12.50 million2.49 millionNot OptionableZVSAZyVersa Therapeutics24.87 million4.86 millionNot OptionableGPLB, GRI, ZVSA, and ENVB HeadlinesRecent News About These CompaniesZyVersa Touches 52-Week Low; Nasdaq to Suspend Trading ThursdayJuly 16, 2025 | marketwatch.comZyVersa Therapeutics (NASDAQ:ZVSA) Upgraded to Hold at Wall Street ZenJuly 14, 2025 | americanbankingnews.comZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | MorningstarJuly 9, 2025 | morningstar.comMZyVersa’s VAR 200 approved for emergency use in rare kidney diseaseJuly 9, 2025 | uk.investing.comZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis - NasdaqJuly 9, 2025 | nasdaq.comWhy Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?July 8, 2025 | benzinga.comZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross ProceedsJuly 8, 2025 | globenewswire.comZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII AmyloidosisJuly 8, 2025 | finanznachrichten.deZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII AmyloidosisJuly 8, 2025 | quiverquant.comQZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII AmyloidosisJuly 8, 2025 | globenewswire.comZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200 - NasdaqJune 27, 2025 | nasdaq.comZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol ...June 26, 2025 | morningstar.comMZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients ...June 26, 2025 | finance.yahoo.comZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediatorâ„¢ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)June 26, 2025 | globenewswire.comZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200June 25, 2025 | quiverquant.comQZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200June 25, 2025 | globenewswire.comZyversa Therapeutics Inc News (ZVSA) - Investing.comJune 25, 2025 | investing.comZVSA - ZyVersa Therapeutics Inc News - MorningstarJune 24, 2025 | morningstar.comMZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s DiseasesMay 22, 2025 | seekingalpha.comZyVersa Therapeutics Highlights New Research Supporting Inflammasome ASC Inhibitor IC 100 as Potential Treatment for Parkinson's DiseaseMay 20, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGPLB, GRI, ZVSA, and ENVB Company DescriptionsEnveric Biosciences NASDAQ:ENVB$1.32 +0.04 (+3.13%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Green Planet Bioengineering OTCMKTS:GPLB$0.04 0.00 (0.00%) As of 07/18/2025Green Planet Bioengineering Co. Ltd. operates as a shell company, with the purpose of acquisition and merging with an existing business operation. The company was founded on October 30, 2006 and is headquartered in Aventura, FL.GRI Bio NASDAQ:GRI$1.82 -0.13 (-6.67%) As of 07/18/2025 03:59 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.ZyVersa Therapeutics NASDAQ:ZVSA$0.14 -0.04 (-22.54%) As of 07/18/2025 04:00 PM EasternZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
